<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Montravers P</submitter><funding>Direction de la Recherche Clinique de l’Assistance Publique des Hôpitaux de Paris</funding><funding>Programme Hospitalier de Recherche Clinique</funding><funding>French Ministry of Health</funding><pagination>3303-3309</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8598293</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>76(12)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Therapeutic failure is a frequent issue in the management of post-operative peritonitis.&lt;h4>Objectives&lt;/h4>A post hoc analysis of the prospective, multicentre DURAPOP trial analysed the risk factors for failures in post-operative peritonitis following adequate source control and empirical antibiotic therapy in critically ill patients.&lt;h4>Patients and methods&lt;/h4>Overall failures assessed post-operatively between Day 8 and Day 45 were defined as a composite of death and/or surgical and/or microbiological failures. Risk factors for failures were assessed using logistic regression analyses.&lt;h4>Results&lt;/h4>Among the 236 analysed patients, overall failures were reported in 141 (59.7%) patients, including 30 (12.7%) deaths, 81 (34.3%) surgical and 95 (40.2%) microbiological fa</pubmed_abstract><journal>The Journal of antimicrobial chemotherapy</journal><pubmed_title>Risk factors for therapeutic failure in the management of post-operative peritonitis: a post hoc analysis of the DURAPOP trial.</pubmed_title><pmcid>PMC8598293</pmcid><funding_grant_id>AOM 09024</funding_grant_id><pubmed_authors>Beaussier M</pubmed_authors><pubmed_authors>Eloy P</pubmed_authors><pubmed_authors>Grall N</pubmed_authors><pubmed_authors>Besch G</pubmed_authors><pubmed_authors>Levrard M</pubmed_authors><pubmed_authors>Lescot T</pubmed_authors><pubmed_authors>Desmard M</pubmed_authors><pubmed_authors>Gaillard T</pubmed_authors><pubmed_authors>Blasco G</pubmed_authors><pubmed_authors>Montravers P</pubmed_authors><pubmed_authors>Herault MC</pubmed_authors><pubmed_authors>Launey Y</pubmed_authors><pubmed_authors>Plantefeve G</pubmed_authors><pubmed_authors>Georger JF</pubmed_authors><pubmed_authors>DURAPOP trial group</pubmed_authors><pubmed_authors>Auboyer C</pubmed_authors><pubmed_authors>Paugam C</pubmed_authors><pubmed_authors>Floch T</pubmed_authors><pubmed_authors>Dupont H</pubmed_authors><pubmed_authors>Pease S</pubmed_authors><pubmed_authors>Jaber S</pubmed_authors><pubmed_authors>Gally J</pubmed_authors><pubmed_authors>Perrier JF</pubmed_authors><pubmed_authors>Gergaud S</pubmed_authors><pubmed_authors>Clavier T</pubmed_authors><pubmed_authors>Raclot P</pubmed_authors><pubmed_authors>Cinotti R</pubmed_authors><pubmed_authors>Tesniere A</pubmed_authors><pubmed_authors>Pily-Floury S</pubmed_authors><pubmed_authors>Veber B</pubmed_authors><pubmed_authors>Seguin P</pubmed_authors><pubmed_authors>Samain E</pubmed_authors><pubmed_authors>Belhadj-Tahar N</pubmed_authors><pubmed_authors>Mignon A</pubmed_authors><pubmed_authors>Pajot O</pubmed_authors><pubmed_authors>Wallet F</pubmed_authors><pubmed_authors>Esposito-Farese M</pubmed_authors><pubmed_authors>Weiss E</pubmed_authors><pubmed_authors>Abback P</pubmed_authors><pubmed_authors>Tassin C</pubmed_authors><pubmed_authors>Cousson J</pubmed_authors><pubmed_authors>Mahjoub Y</pubmed_authors><pubmed_authors>Payen JF</pubmed_authors><pubmed_authors>Delay JM</pubmed_authors><pubmed_authors>Gouin P</pubmed_authors><pubmed_authors>Asehnoune K</pubmed_authors><pubmed_authors>Jung B</pubmed_authors><pubmed_authors>Girard C</pubmed_authors><pubmed_authors>Bronchard R</pubmed_authors><pubmed_authors>Collanges O</pubmed_authors><pubmed_authors>Lepape A</pubmed_authors><pubmed_authors>Meistelman C</pubmed_authors><pubmed_authors>Piriou V</pubmed_authors><pubmed_authors>Lasocki S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Risk factors for therapeutic failure in the management of post-operative peritonitis: a post hoc analysis of the DURAPOP trial.</name><description>&lt;h4>Background&lt;/h4>Therapeutic failure is a frequent issue in the management of post-operative peritonitis.&lt;h4>Objectives&lt;/h4>A post hoc analysis of the prospective, multicentre DURAPOP trial analysed the risk factors for failures in post-operative peritonitis following adequate source control and empirical antibiotic therapy in critically ill patients.&lt;h4>Patients and methods&lt;/h4>Overall failures assessed post-operatively between Day 8 and Day 45 were defined as a composite of death and/or surgical and/or microbiological failures. Risk factors for failures were assessed using logistic regression analyses.&lt;h4>Results&lt;/h4>Among the 236 analysed patients, overall failures were reported in 141 (59.7%) patients, including 30 (12.7%) deaths, 81 (34.3%) surgical and 95 (40.2%) microbiological fa</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Nov</publication><modification>2026-07-14T13:22:23.57Z</modification><creation>2022-02-11T13:01:29.203Z</creation></dates><accession>S-EPMC8598293</accession><cross_references><pubmed>34458922</pubmed><doi>10.1093/jac/dkab307</doi></cross_references></HashMap>